Pfizer tests drug interactions in healthy volunteers
NCT ID NCT06837259
First seen Feb 02, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This completed Phase 1 study looked at how two common drugs—cyclosporine (an immunosuppressant) and clarithromycin (an antibiotic)—affect the levels of a new medicine called PF-07328948 in the body. Twenty-six healthy adults received PF-07328948 alone and then with cyclosporine or clarithromycin. The goal was to understand drug interactions, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07328948, cyclosporine, clarithromycin
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.